CN105025924A - 经诱导树突细胞及其用途 - Google Patents

经诱导树突细胞及其用途 Download PDF

Info

Publication number
CN105025924A
CN105025924A CN201480008074.8A CN201480008074A CN105025924A CN 105025924 A CN105025924 A CN 105025924A CN 201480008074 A CN201480008074 A CN 201480008074A CN 105025924 A CN105025924 A CN 105025924A
Authority
CN
China
Prior art keywords
cells
human
mice
cell
smyledc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480008074.8A
Other languages
English (en)
Chinese (zh)
Inventor
雷娜塔·斯特里波克
古斯塔沃·萨尔格罗-洛佩兹
阿努萨拉·登塔那塞马克
阿诺德·甘泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Hochschule Hannover
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of CN105025924A publication Critical patent/CN105025924A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CN201480008074.8A 2013-02-07 2014-01-24 经诱导树突细胞及其用途 Pending CN105025924A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/052485 2013-02-07
PCT/EP2013/052485 WO2014121840A1 (en) 2013-02-07 2013-02-07 Induced dendritic cells and uses thereof
PCT/EP2014/051422 WO2014122035A2 (en) 2013-02-07 2014-01-24 Induced dendritic cells and uses thereof

Publications (1)

Publication Number Publication Date
CN105025924A true CN105025924A (zh) 2015-11-04

Family

ID=47664310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480008074.8A Pending CN105025924A (zh) 2013-02-07 2014-01-24 经诱导树突细胞及其用途

Country Status (5)

Country Link
US (2) US10272111B2 (enExample)
JP (1) JP6866988B2 (enExample)
CN (1) CN105025924A (enExample)
CA (1) CA2899786C (enExample)
WO (2) WO2014121840A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105039256A (zh) * 2015-07-13 2015-11-11 中政道和（北京）生物科技有限公司 一种支气管镜下获取肿瘤组织进行树突细胞培养扩增方法
CN109310709A (zh) * 2015-12-30 2019-02-05 细胞基因公司 T淋巴细胞生产方法和由此产生的t淋巴细胞
CN110337446A (zh) * 2016-12-21 2019-10-15 佛罗里达大学研究基金会 过继细胞疗法中ccr2+造血干细胞介导的t细胞激活
CN110914411A (zh) * 2017-05-10 2020-03-24 奥胡斯大学 干扰素引发的浆细胞样树突细胞
CN111647563A (zh) * 2020-08-06 2020-09-11 北京翊博普惠生物科技发展有限公司 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用
WO2024045890A1 (zh) * 2022-08-30 2024-03-07 浙江吉量科技有限公司 树突细胞祖细胞的制备方法及其培养基

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060566B2 (en) 2017-08-22 2024-08-13 The Regents Of The University Of California Self-inactivating lentiviral vector comprising a FOXP3 expression cassette
KR20210044207A (ko) 2018-07-15 2021-04-22 이노치안 바이오파마, 인코포레이티드 암 치료를 위한 재조합 수지상 세포를 사용하는 방법 및 조성물
US10980836B1 (en) * 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
IL293718A (en) * 2019-12-11 2022-08-01 Myeloid Therapeutics Inc Therapeutic cell compositions and methods for manufacture and uses thereof
WO2021243190A1 (en) * 2020-05-28 2021-12-02 Biomagnetic Solutions Llc Compositions and methods for negative selection of naive t and b cells with a single antibody
WO2022108306A1 (ko) * 2020-11-17 2022-05-27 성균관대학교산학협력단 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물
AU2022237618A1 (en) 2021-03-17 2023-10-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
JP2024518100A (ja) 2021-05-11 2024-04-24 マイエロイド・セラピューティクス，インコーポレーテッド ゲノム組込みのための方法および組成物
CN113881631B (zh) * 2021-10-11 2022-08-02 北京翊博普惠生物科技发展有限公司 一种扁桃体来源的Tγδ细胞及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531896A (ja) * 2009-06-29 2012-12-13 チェン，チンフェン ヒト化非ヒト哺乳動物を製造する方法
DE102012207453B4 (de) 2012-05-04 2017-10-19 Technische Universität Dresden Humanisierte Mäuse ohne Konditionierung

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANUSARA DAENTHANASANMAK ET AL.: "Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo", 《VACCINE》 *
刘宁飞等: "大白鼠淋巴结移植—功能结构和细胞学的变化以及影响其再生的因素", 《中国修复重建外科杂志》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105039256A (zh) * 2015-07-13 2015-11-11 中政道和（北京）生物科技有限公司 一种支气管镜下获取肿瘤组织进行树突细胞培养扩增方法
CN109310709A (zh) * 2015-12-30 2019-02-05 细胞基因公司 T淋巴细胞生产方法和由此产生的t淋巴细胞
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
CN110337446A (zh) * 2016-12-21 2019-10-15 佛罗里达大学研究基金会 过继细胞疗法中ccr2+造血干细胞介导的t细胞激活
CN110337446B (zh) * 2016-12-21 2024-06-18 佛罗里达大学研究基金会 过继细胞疗法中ccr2+造血干细胞介导的t细胞激活
CN110914411A (zh) * 2017-05-10 2020-03-24 奥胡斯大学 干扰素引发的浆细胞样树突细胞
CN111647563A (zh) * 2020-08-06 2020-09-11 北京翊博普惠生物科技发展有限公司 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用
WO2024045890A1 (zh) * 2022-08-30 2024-03-07 浙江吉量科技有限公司 树突细胞祖细胞的制备方法及其培养基

Also Published As

Publication number Publication date
WO2014122035A2 (en) 2014-08-14
JP6866988B2 (ja) 2021-04-28
CA2899786A1 (en) 2014-08-14
US10272111B2 (en) 2019-04-30
US11413307B2 (en) 2022-08-16
JP2016513953A (ja) 2016-05-19
US20160038541A1 (en) 2016-02-11
WO2014122035A9 (en) 2014-12-11
WO2014121840A1 (en) 2014-08-14
US20190247430A1 (en) 2019-08-15
WO2014122035A3 (en) 2014-10-23
CA2899786C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
US11413307B2 (en) Induced dendritic cells and uses thereof
JP7351533B2 (ja) 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
ES2991327T3 (es) Proteína de fusión para la utilización en el tratamiento de la enfermedad EHCI
Salguero et al. Dendritic cell–mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation
ES2931530T3 (es) Método para generar progenitores de células T
US20140057354A1 (en) Antigen-specific regulatory t-cell induction
Lee et al. IL-4 induced innate CD8+ T cells control persistent viral infection
Norton et al. Lentiviral vector-based dendritic cell vaccine suppresses HIV replication in humanized mice
Daenthanasanmak et al. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV
RS62619B1 (sr) Genska terapija
US20230210902A1 (en) Sars-cov-2-specific t cells
Dörrie et al. Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation
WO2017103613A1 (en) Treatment
CN116323921A (zh) 从人多能干细胞生成cd4+效应t细胞和调节性t细胞
Ha et al. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity
EP2953644B1 (en) Induced dendritic cells and uses thereof
Salguero et al. Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD. Rag1−/−. IL-2rγc−/− mice
Ramírez et al. Impact of T cell selection methods in the success of clinical adoptive immunotherapy
Bauer et al. Gene Therapy for HIV: From Inception to a Possible Cure
Macke et al. Dendritic Cell
Preece et al. Allo-defensive, multiplex base-edited, anti-CD38 CAR T cells for ‘off-the-shelf’Immunotherapy
Li Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cells for Cancer Immunotherapy
Panchal Developing novel therapies for X-linked lymphoproliferative disease type 1
Holguin Novel Humanized Mouse Models with Delayed Onset of GVHD for Preclinical HIV Research
Nagy Acceptance of allogeneic cell transplants without systemic immune suppression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20151104

RJ01 Rejection of invention patent application after publication